Abstract:While the antibody response to SARS-CoV-2 has been extensively studied in blood, relatively little is known about the mucosal immune response and its relationship to systemic antibody levels. Since SARS-CoV-2 initially replicates in the upper airway, the antibody response in the oral cavity is likely an important parameter that influences the course of infection, but how it correlates to the antibody response in serum is not known. Here, we profile by enzyme linked immunosorbent assays (ELISAs) IgG, IgA and IgM responses to the SARS-CoV-2 spike protein (full length trimer) and its receptor binding domain (RBD) in serum (n=496) and saliva (n=90) of acute and convalescent patients with laboratory-diagnosed COVID-19 ranging from 3–115 days post-symptom onset (PSO), compared to negative controls. Anti-CoV-2 antibody responses were readily detected in serum and saliva, with peak IgG levels attained by 16–30 days PSO. Whereas anti-CoV-2 IgA and IgM antibodies rapidly decayed, IgG antibodies remained relatively stable up to 105 days PSO in both biofluids. In a surrogate neutralization ELISA (snELISA), neutralization activity peaks by 31–45 days PSO and slowly declines, though a clear drop is detected at the last blood draw (105–115 days PSO). Lastly, IgG, IgM and to a lesser extent IgA responses to spike and RBD in the serum positively correlated with matched saliva samples. This study confirms that systemic and mucosal humoral IgG antibodies are maintained in the majority of COVID-19 patients for at least 3 months PSO. Based on their correlation with each other, IgG responses in saliva may serve as a surrogate measure of systemic immunity. One Sentence Summary In this manuscript, we report evidence for sustained SARS-CoV-2-specific IgG and transient IgA and IgM responses both at the site of infection (mucosae) and systemically in COVID-19 patients over 3 months and suggest that saliva could be used as an alternative biofluid for monitoring IgG to SARS-CoV-2 spike and RBD antigens. ### Competing Interest Statement Steven J Drews has acted as a content expert for respiratory viruses for Johnson & Johnson (Janssen). Work in the Gingras lab was partially funded by a contribution from QuestCap through the Sinai Health Foundation; QuestCap also funds work in the Mubareka lab. Work in the Gommerman lab unrelated to this project has been funded by EMD-Serono, Roche and Novartis. ### Funding Statement This study was supported by an Ontario Together grant and funding from the Canadian Institutes of Health Research (CIHR; #VR1-172711 and VR4-172732). Funding for the development of the assays in the Gingras lab was provided through generous donations from the Royal Bank of Canada (RBC), Questcap and the Krembil Foundation to the Sinai Health System Foundation. The robotics equipment used is housed in the Network Biology Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a facility supported by Canada Foundation for Innovation funding, by the Ontarian Government and by Genome Canada and Ontario Genomics (OGI-139). Indirect support for SARS-CoV-2 work in the Toronto Combined Containment Level 3 laboratory was provided by strategic research funds from the University of Toronto and the Temerity Foundation. MO is funded by: OHTN (Ontario HIV Treatment Network), CIHR and the Juan and Stefania Speck Fund. JG is a Canada Research Chair, Tier 1, in Tissue Specific Immunity and is supported by CIHR FDN15992. ACG is the Canada Research Chair, Tier 1, in Functional Proteomics and is supported by CIHR FDN143301. AJJ is supported by a Vanier Canada graduate studentship. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: REB studies #20-044 Unity Health Network; #02-0118-U/05-0016-C, Mount Sinai Hospital; REB study# 23901 University of Toronto; REB studies #01-0138-U and #01-0347-U, Mount Sinai Hospital; REB studies #31593 University of Toronto, #05-0869, University Health Network All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All the aggregate data is available in the manuscript; access to the raw, unprocessed data is available upon request.

Subclinical SARS-CoV-2 Infections and Endemic Human Coronavirus Immunity Shape SARS-CoV-2 Saliva Antibody Responses

Salivary immune responses after COVID-19 vaccination

Assessing Mucosal Antibody Responses to SARS-CoV-2 in Humans and Mice

Comparison of levels of nasal, salivary, and plasma antibody to SARS-CoV-2 during natural infection and after vaccination

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection

Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19

SARS-CoV-2-Specific Immune Responses in Vaccination and Infection during the Pandemic in 2020–2022

Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum

Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections

Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial

Oral SARS-CoV-2 host responses predict the early COVID-19 disease course

Early, robust mucosal secretory IgA but not IgG response to SARS-CoV-2 spike in oral fluid is associated with faster viral clearance and COVID-19 symptom resolution.

Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients

Serum and Salivary IgG and IgA Response After COVID-19 mRNA Vaccination

Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva

Systemic SARS-CoV-2-specific antibody responses to infection and to COVID-19 and BCG vaccination

Early, robust mucosal secretory IgA but not IgG response to SARS-CoV-2 spike in oral fluid is associated with faster viral clearance and COVID-19 symptom resolution

SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms

Immune Dysregulation in the Oral Cavity during Early SARS-CoV-2 Infection

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in patients with COVID-19